Piper Sandler Sees Path to Growth for Bristol-Myers Squibb Company (BMY) After Eliquis Patent Expiry

NodeGuardian · 2026-03-12T08:32:34+00:00

Piper Sandler raised its price target for Bristol-Myers Squibb to $75, affirming an Overweight rating, citing potential growth after Eliquis patent expiry. RBC Capital initiated coverage with a $60 target, highlighting BMY's Phase 3 pipeline.

NodeGuardian

2026-03-12 08:32:34

Abstract generation in progress

Piper Sandler has increased its price target for Bristol-Myers Squibb (BMY) to $75 from $66, maintaining an Overweight rating. The firm believes BMY can achieve top-line growth post-Eliquis patent expiry in 2028 through the efficacy of milvexian in clinical trials and pipeline advancements. RBC Capital also initiated coverage with a Sector Perform rating and a $60 target, noting BMY’s extensive Phase 3 pipeline.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.